1 

UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF ILLINOIS 

EASTERN DIVISION 

BCBSM, INC., et al., 

 Plaintiffs / Counter-Defendants, 

v. 

WALGREEN CO. & WALGREENS 

BOOTS ALLIANCE, INC., 

 Defendants / Counterclaimant. 

) 

) 

) 

) 

) 

) 

) 

) 

) 

) 

) 

) 

) 

Case No. 1:20-cv-01853 

Honorable Virginia M. Kendall 

Honorable Sheila M. Finnegan 

Consolidated with: 

No. 1:20-cv-01929 

No. 1:20-cv-03332 

No. 1:20-cv-04738 

No. 1:20-cv-04940 

No. 1:22-cv-01362 

WALGREEN CO. & WALGREENS 

BOOTS ALLIANCE, INC., 

 Third-Party Plaintiffs, 

v. 

PRIME THERAPEUTICS LLC & 

OMEDARX, INC.,

 Third-Party Defendant. 

) 

) 

) 

) 

) 

) 

) 

) 

) 

) 

) 

 

DECLARATION OF TIMOTHY R. FARRELL IN SUPPORT OF 

DEFENDANTS’ OPPOSITION TO PLAINTIFFS’ 

MOTION TO COMPEL CLAWED BACK DOCUMENTS 

I, Timothy R. Farrell, hereby declare, pursuant to 28 U.S.C. § 1746, that the following facts 

are true and accurate to the best of my knowledge and belief. 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 1 of 172 PageID #:10800
2 

1. I am an attorney at Ropes & Gray LLP and counsel to Walgreen Co. and Walgreens 

Boots Alliance, Inc. (together with Walgreen Co., “Defendants”). I am a member of the Illinois 

bar, and I am admitted to practice before the United States District Court for the Northern District 

of Illinois. 

2. I submit this declaration with and in support of Defendants’ Opposition to 

Plaintiffs’ Motion to Compel Clawed Back Documents. 

3. On June 6, 2023, Plaintiffs deposed former Walgreens employee Joseph Kristie in 

connection with this case. I represented Mr. Kristie at the deposition. Plaintiffs attached a transcript 

of this deposition testimony to the declaration of Justin D. Kingsolver (“Kingsolver Decl.”) as 

Exhibit 3. Attached hereto as Exhibit 1 is a true and accurate copy of the document introduced as 

Exhibit 129 at Mr. Kristie’s deposition (“Kristie Ex. 129”). 

4. Attached hereto as Exhibit 2 is a true an accurate copy of a document produced by 

Walgreens bearing Bates number WAG_BCBS00586765 through WAG_BCBS00586767. This 

document is one of three near-duplicate versions of the same email chain represented in Kristie 

Ex. 129 that had the privileged information redacted and was available to Plaintiffs’ counsel in 

advance of the Kristie deposition. Walgreens had previously produced two other versions of this 

same email chain with the privileged material redacted. 

5. In July 2023, Walgreens’ counsel in this action discovered an email from 

Walgreens senior attorney Daniel Fitzgerald to Megan Butterfield in which Mr. Fitzgerald 

expressly directed Ms. Butterfield and others 

(the “Email Directive”). Counsel at 

my firm then searched for and reviewed all PSC-related communications stemming from the Email 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 2 of 172 PageID #:10801
3 

Directive, including any such communications with other executives and specialists that counsel 

identified as involved in the counsel-directed project, such as Blake Slansky and Andy Fox. 

6. In consultation with Walgreens’ in-house counsel and based on my firm’s review 

of the record, we confirmed that Nabeel Ahmed’s 

 ordered by Walgreens in-house counsel in the Email Directive. 

Counsel’s review also confirmed that Paul Vroman created a as directed 

in the Email Directive. 

7. Documents produced by Walgreens reflect Mr. Ahmed’s work alongside senior 

Walgreens executives with respect to 

, such as Exhibit 3, which is a true an accurate copy of a document produced by 

Walgreens bearing Bates number WAG_BCBS01612209 through WAG_BCSB01612214. 

8. Documents produced by Walgreens reflect Walgreens’ leadership involving 

, such as Exhibit 4, which is a true an 

accurate copy of a document produced by Walgreens bearing Bates number 

WAG_BCBS00612483 through WAG_BCBS00612488. 

9. Attached hereto as Exhibit 5 is a true and accurate copy of transcript excerpts from 

the 30(b)(6) deposition of Walgreens through representative Scott Schuler in Russo v. Walgreen 

Co., No. 1:17-cv-2246 (N.D. Ill.), dated October 5, 2018. Walgreens’ testimony through 

representative Mr. Schuler in the Rule 30(b)(6) deposition taken in Russo v. Walgreen Co., No. 

1:17-cv-2246 (N.D. Ill.) describes Mr. Hohmeier’s role in assisting leadership’s pricing decisions. 

See Ex. 5, at Tr. 93:11–18. 

10. Documents produced by Walgreens reflect Dustin Thomas’s involvement and 

provision of opinions on drug pricing to Walgreens leadership, including Megan Butterfield and 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 3 of 172 PageID #:10802
4 

Rick Gates, Vice President – Pharmacy Operations, such as Exhibit 6, which is a true an accurate 

copy of a document produced by Walgreens bearing Bates number WAG_BCBS00029808 

through WAG_BCBS00029822. 

11. Documents produced by Walgreens reflect Grace Noboa-Hidalgo’s work with 

Walgreens leadership in planning related to the consumer-paid markets, such as Exhibit 7, a true 

an accurate copy of a document produced by Walgreens bearing Bates number 

WAG_BCBS01343209. 

12. On September 1, 2023, Walgreens issued a Notice of Inadvertent Disclosure of 

Privileged Material (the “Notice”) to Plaintiffs, a copy of which is attached as Exhibit 4 to the 

Kingsolver Declaration. 

13. On September 11, 2023, Plaintiffs issued a letter to Walgreens responding to the 

Notice, a copy of which is attached as Exhibit 5 to the Kingsolver Declaration. In the letter, 

Plaintiffs challenged Walgreens’ clawing back of one document included in the notice—

specifically, Kristie Ex. 129. Plaintiffs’ letter did not challenge any other documents that 

Walgreens clawed back. Plaintiffs’ letter also never argued that Walgreens waived any privilege 

over any other documents. 

14. On September 14, 2023, Walgreens sent a response letter to Plaintiffs, a copy of 

which is attached as Exhibit 6 to the Kingsolver Declaration. In this letter, Walgreens corrected 

misstatements in Plaintiffs’ September 11 letter and explained the privileged nature of Kristie Ex. 

129. Walgreens also reiterated its concerns regarding Mr. Kingsolver’s questions during the Kristie 

deposition about Kristie Ex. 129. 

15. On September 21, 2023, Walgreens’ counsel (I with my colleagues Jeffrey 

Bushofsky, Nicholas Smith, and Tyler Paladino of Ropes & Gray LLP), and Plaintiffs’ counsel 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 4 of 172 PageID #:10803
5 

(Justin Kingsolver and Michael Pine of Crowell & Moring LLP), conferred by videoconference in 

an attempt to resolve issues related to the clawed back documents. During the discussion, 

Plaintiffs’ counsel expressly withdrew any dispute regarding Walgreens’ privilege claim over 

Kristie Ex. 129, advising Walgreens’ counsel that Plaintiffs were not contesting that clawback. 

Plaintiffs challenged Walgreens’ withholding of documents related to the Email Directive, to 

which Walgreens’ counsel reiterated the argument made in the Notice that these documents were 

created expressly at the direction of counsel. Plaintiffs’ counsel argued that the production of these 

documents in prior litigation waived privilege in this case, and that Walgreens waived any chance 

at further redacting previously redacted documents produced in the prior litigations. I explained 

that Walgreens was still entitled to claw back and redact these documents based on the parties’ 

Agreed Amended Confidentiality Order (“AACO”) and the Rule 502(d) order. 

16. On October 2, 2023, Walgreens’ counsel (I and my colleagues Nicholas Smith and 

Tyler Paladino) and Plaintiffs’ counsel (Justin Kingsolver and Michael Pine) again conferred by 

video-conference in another good faith attempt to resolve issues related to the clawed back 

documents. During this discussion, I disagreed with Plaintiffs’ purported reliance on certain case 

law, explaining that those cases did not involve Rule 502(d) orders, and thus were entirely 

distinguishable here where any Walgreens productions—whether in this case or in prior 

litigations—were made pursuant to applicable Rule 502(d) orders. I stated that the documents were 

in the process of being clawed back in the other litigations, and described how it had not been clear 

in those cases that the documents being clawed back flowed from the Email Directive. Plaintiffs’ 

counsel disputed this claim and reiterated their previous arguments about waiver, as argued on the 

September 21 meet and confer. At the end of the call, Plaintiffs’ counsel asked whether Walgreens 

would stipulate to the application of Illinois choice of law principles for purposes of motion 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 5 of 172 PageID #:10804
6 

practice. However, when discussing this issue, Plaintiffs did not raise any waiver argument or 

theory based on the application of Illinois law’s control group test, nor did they mention the control 

group test whatsoever. Plaintiffs also did not raise an argument regarding application of the 

“control group” test in response to Walgreens’ previous notices of inadvertent disclosure or in their 

motion to compel filed October 11, 2022. Finally, Plaintiffs promised to follow up with a list of 

redactions that they specifically challenged. 

17. On October 2, 2023, Walgreens clawed back most of the documents identified in 

the Notice in two prior cases: Russo v. Walgreen Co., No. 1:17-cv-2246 (N.D. Ill.) and Humana 

Health Plan, Inc. v. Walgreen Co., AAA Case No. 01-19-0002-5131. Walgreens clawed back these 

documents pursuant to the protective orders, both invoking Rule 502(d), entered in those 

litigations. 

18. On October 9, 2023, Plaintiffs emailed Walgreens identifying only two documents 

for which it challenged the proposed redactions. One of which was Kristie Ex. 129, for which they 

had already agreed to withdraw their challenge to Walgreens’ privilege claim. The next day, 

Walgreens responded that the redacted information was privileged because it either detailed the 

contents of legal advice, stemmed from the Email Directive, or described the rationale on which 

Walgreens’ counsel provided legal advice. A true and accurate copy of excerpts of this meet and 

confer email correspondence is included in the email chain attached hereto as Exhibit 8. 

19. During the meet-and-confer process, Plaintiffs’ counsel did not raise any waiver 

argument based on Illinois’ control group test. 

20. The parties have not yet exchanged privilege logs in this matter, except for limited 

logs of certain documents subject to inadvertent-disclosure notices. 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 6 of 172 PageID #:10805
7 

21. Attached hereto as Exhibit 9 is a true and accurate copy of the qui tam Complaint 

filed under seal on January 13, 2012 in United States ex rel. Baker v. Walgreen, Co., No. 1:12-cv300 (S.D.N.Y) in the Southern District of New York. 

22. Attached hereto as Exhibit 10 is a true and accurate copy of the first of multiple 

Civil Investigative Demands the Department of Justice issued to Walgreens relating to PSC, issued 

on July 5, 2012. 

23. Attached hereto as Exhibit 11 is a true and accurate copy of a settlement reached 

on January 18, 2017, Stipulation & Order of Settlement & Release, Baker, No. 1:12-cv-300 

(S.D.N.Y.), Dkt. Nos. 23, resolving certain claims brought against Walgreens in the Baker

litigation. 

24. Attached hereto as Exhibit 12 is a true and accurate copy of a settlement reached 

on January 15, 2019, Stipulation & Order of Settlement & Release, Baker, No. 1:12-cv-300 

(S.D.N.Y.), Dkt. Nos. 53, resolving the remaining claims brought against Walgreens in the Baker

litigation. 

25. Attached hereto as Exhibit 13 is a true and accurate copy of excerpts of the 

transcript of the deposition of Megan Butterfield in Russo v. Walgreen Co., No. 1:17-cv-2246 

(N.D. Ill.), dated December 5, 2019. 

26. Attached hereto as Exhibit 14 is a true and accurate copy of excerpts of the 

transcript of the deposition of Blake Slansky in Russo v. Walgreen Co., No. 1:17-cv-2246 (N.D. 

Ill.), dated November 22, 2019. 

I declare under penalty of perjury that the foregoing is true and correct. Executed this 1st

day of November, 2023. 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 7 of 172 PageID #:10806
8 

 ____/s/ Timothy R. Farrell_______ 

Timothy R. Farrell 

ROPES & GRAY LLP 

191 North Wacker Drive, 32nd Floor 

Chicago, Illinois 60606 

Tel: (312) 845-1209 

Fax: (312) 845-5569 

Timothy.Farrell@ropesgray.com 

Attorney for Defendant / Counterclaimant / 

Third-Party Plaintiff Walgreen Co. & 

Defendant / Third-Party Plaintiff Walgreens 

Boots Alliance, Inc. 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 8 of 172 PageID #:10807
CERTIFICATE OF SERVICE 

I, Charles D. Zagnoli, hereby certify that the forgoing document was electronically filed 

on November 1, 2023, and will be served electronically via the Court’s ECF Notice system upon 

all registered counsel of record. 

__/s/ Charles D. Zagnoli_________ 

Charles D. Zagnoli 

ROPES & GRAY LLP 

191 North Wacker Drive, 32nd Floor 

Chicago, Illinois 60606 

Tel: (312) 845-1209 

Fax: (312) 845-5569 

Charles.Zagnoli@ropesgray.com 

Attorney for Defendant / Counterclaimant / ThirdParty Plaintiff Walgreen Co. & Defendant / ThirdParty Plaintiff Walgreens Boots Alliance, Inc. 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 9 of 172 PageID #:10808
Farrell Decl. 

Exhibit 1 

 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 10 of 172 PageID #:10809
Filed Under Seal 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 11 of 172 PageID #:10810
Farrell Decl. 

Exhibit 2 

 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 12 of 172 PageID #:10811
Filed Under Seal 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 13 of 172 PageID #:10812
Farrell Decl. 

Exhibit 3 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 14 of 172 PageID #:10813
Filed Under Seal 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 15 of 172 PageID #:10814
Farrell Decl. 

Exhibit 4 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 16 of 172 PageID #:10815
Filed Under Seal 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 17 of 172 PageID #:10816
Farrell Decl. 

Exhibit 5 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 18 of 172 PageID #:10817
Filed Under Seal 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 19 of 172 PageID #:10818
Farrell Decl. 

Exhibit 6 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 20 of 172 PageID #:10819
Filed Under Seal 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 21 of 172 PageID #:10820
Farrell Decl. 

Exhibit 7 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 22 of 172 PageID #:10821
Filed Under Seal 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 23 of 172 PageID #:10822
Farrell Decl. 

Exhibit 8 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 24 of 172 PageID #:10823
From: Smith, Nicholas

To: JKingsolver@crowell.com; Farrell, Timothy

Cc: Mpine@crowell.com; Zagnoli, Charles; Bushofsky, Jeffrey J.; KHibbert@crowell.com; Lewis, Matthew

Subject: RE: BCBS v. Walgreens - Walgreens Fourth Notice of Inadvertent Disclosure

Date: Tuesday, October 10, 2023 7:32:06 PM

Justin,

Thank you for providing a list of the as-applied redactions with which you take issue with respect to

two documents only. We understand this means you are not challenging the redactions applied to

other documents in the relevant clawback population. We have reviewed the redactions you

challenge, and will not be withdrawing the associated privilege claims as to the redactions in those

two documents.

With regard to WAG_BCSB00159631, all the information contained in both challenged slides is

privileged. 

.

Next, we appreciate your willingness to continue to meet and confer regarding the documents you

contend were previously introduced as exhibits in other cases. We do not believe, based on the case

law and other information you’ve provided in challenging these privilege assertions, that your

challenges are supported. Instead, we believe your clients’ challenges purport to avoid the terms

regarding inadvertent disclosures to which they agreed in the protective order. Walgreens

accordingly stands by its privilege assertions as to those documents. 

To the extent you do intend to file a motion, we trust that you will file said motion under seal in

compliance with your obligations set forth in the inadvertent disclosure provisions of this case’s

relevant orders.

Best,

Nick

From: Kingsolver, Justin <JKingsolver@crowell.com> 

Sent: Monday, October 09, 2023 3:48 PM

To: Smith, Nicholas <Nicholas.Smith@ropesgray.com>; Farrell, Timothy

<Timothy.Farrell@ropesgray.com>

Cc: Mpine@crowell.com; Zagnoli, Charles <Charles.Zagnoli@ropesgray.com>; Bushofsky, Jeffrey J.

<Jeffrey.Bushofsky@ropesgray.com>; KHibbert@crowell.com; Lewis, Matthew

<MLewis@crowell.com>

Subject: RE: BCBS v. Walgreens - Walgreens Fourth Notice of Inadvertent Disclosure

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 25 of 172 PageID #:10824
[EXTERNAL]

Counsel:

Following up on our meet and confer, we have concerns with respect to the following redactions.

1. WAG_BCBS00159631

Slide 26 redacts out the entirety of the information besides the title.

 does not make clear that everything in the slide is a

privileged communication. For example, what is the basis for redacting out a 

Slide 48 is entirely redacted. It is not possible to tell from this redaction the basis of any

of the redaction. Is Walgreens taking the position that the 

 in this deck is itself privileged?

2. WAG_BCBS00649215

While we understand your position that anything from “legal” is to be redacted as legal

communication, we do not believe the redaction of the 

 is appropriate. 

Finally, ahead of our planned motion filing deadline on Wednesday, we wanted to make one more

good faith attempt to resolve issues short of motions practice. To that end, will Walgreens agree to

withdraw its clawback claims on the documents previously used as exhibits in Forth or Humana?

Thanks,

Justin

Justin D. Kingsolver

Crowell & Moring LLP

jkingsolver@crowell.com

+1.202.624.2927 direct

From: Kingsolver, Justin 

Sent: Sunday, October 1, 2023 7:51 PM

To: 'Smith, Nicholas' <Nicholas.Smith@ropesgray.com>; Farrell, Timothy

<Timothy.Farrell@ropesgray.com>

Cc: Pine, Michael <Mpine@crowell.com>; Zagnoli, Charles <Charles.Zagnoli@ropesgray.com>;

Bushofsky, Jeffrey J. <Jeffrey.Bushofsky@ropesgray.com>; Hibbert, Kelly <KHibbert@crowell.com>;

Lewis, Matthew <MLewis@crowell.com>

Subject: RE: BCBS v. Walgreens - Walgreens Fourth Notice of Inadvertent Disclosure

Counsel:

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 26 of 172 PageID #:10825
As noted in my earlier email, Plaintiffs are continuing to investigate the documents that are subject

to Defendants’ clawback. Resulting from this narrowing review, attached is an updated list of the

documents which we believe appeared as exhibits in previous cases.

Thanks,

Justin

Justin D. Kingsolver

Crowell & Moring LLP

jkingsolver@crowell.com

+1.202.624.2927 direct

From: Smith, Nicholas <Nicholas.Smith@ropesgray.com> 

Sent: Friday, September 29, 2023 1:34 PM

To: Kingsolver, Justin <JKingsolver@crowell.com>; Farrell, Timothy

<Timothy.Farrell@ropesgray.com>

Cc: Pine, Michael <Mpine@crowell.com>; Zagnoli, Charles <Charles.Zagnoli@ropesgray.com>;

Bushofsky, Jeffrey J. <Jeffrey.Bushofsky@ropesgray.com>; Hibbert, Kelly <KHibbert@crowell.com>

Subject: RE: BCBS v. Walgreens - Walgreens Fourth Notice of Inadvertent Disclosure

External Email

Justin,

I will circulate an invite for 2:30 ET / 1:30 CT, which appears to work for everyone on our end.

Best,

Nick

Nicholas W. Smith

ROPES & GRAY LLP

T +1 312 845 1384

191 North Wacker Drive, 32nd Floor

Chicago, IL 60606

Nicholas.Smith@ropesgray.com

www.ropesgray.com

This message (including attachments) is privileged and confidential. If you are not the intended recipient,

please delete it without further distribution and reply to the sender that you have received the message in

error.

From: Kingsolver, Justin <JKingsolver@crowell.com> 

Sent: Friday, September 29, 2023 3:30 PM

To: Smith, Nicholas <Nicholas.Smith@ropesgray.com>; Farrell, Timothy

<Timothy.Farrell@ropesgray.com>

Cc: Mpine@crowell.com; Zagnoli, Charles <Charles.Zagnoli@ropesgray.com>; Bushofsky, Jeffrey J.

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 27 of 172 PageID #:10826
<Jeffrey.Bushofsky@ropesgray.com>; KHibbert@crowell.com

Subject: RE: BCBS v. Walgreens - Walgreens Fourth Notice of Inadvertent Disclosure

Hi Nick:

My apologies for the delay. I now need to be on a flight on Monday until 1:45pm ET. To be safe,

could we schedule our M&C for 2:15pm ET? I will be joining via phone.

Thanks,

Justin

Justin D. Kingsolver

Crowell & Moring LLP

jkingsolver@crowell.com

+1.202.624.2927 direct

From: Smith, Nicholas <Nicholas.Smith@ropesgray.com> 

Sent: Wednesday, September 27, 2023 2:18 PM

To: Kingsolver, Justin <JKingsolver@crowell.com>; Farrell, Timothy

<Timothy.Farrell@ropesgray.com>

Cc: Pine, Michael <Mpine@crowell.com>; Zagnoli, Charles <Charles.Zagnoli@ropesgray.com>;

Bushofsky, Jeffrey J. <Jeffrey.Bushofsky@ropesgray.com>; Hibbert, Kelly <KHibbert@crowell.com>

Subject: RE: BCBS v. Walgreens - Walgreens Fourth Notice of Inadvertent Disclosure

External Email

Justin,

Thank you for sending this list.

We agree with your proposal to reschedule the meet and confer to Monday, October 2. Would 2 ET

/ 1 CT work on your end? If so, we are happy to send a calendar invite.

Best,

Nick

Nicholas W. Smith

ROPES & GRAY LLP

T +1 312 845 1384

191 North Wacker Drive, 32nd Floor

Chicago, IL 60606

Nicholas.Smith@ropesgray.com

www.ropesgray.com

This message (including attachments) is privileged and confidential. If you are not the intended recipient,

please delete it without further distribution and reply to the sender that you have received the message in

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 28 of 172 PageID #:10827
error.

From: Kingsolver, Justin <JKingsolver@crowell.com> 

Sent: Wednesday, September 27, 2023 2:19 PM

To: Farrell, Timothy <Timothy.Farrell@ropesgray.com>; Smith, Nicholas

<Nicholas.Smith@ropesgray.com>

Cc: Mpine@crowell.com; Zagnoli, Charles <Charles.Zagnoli@ropesgray.com>; Bushofsky, Jeffrey J.

<Jeffrey.Bushofsky@ropesgray.com>; KHibbert@crowell.com

Subject: RE: BCBS v. Walgreens - Walgreens Fourth Notice of Inadvertent Disclosure

Tim,

My apologies, but the holiday schedule got the best of me. Attached, recognizing that it has taken

more time than anticipated, is a list of clawed-back documents that we believe have previously

appeared in substantially-similar form as exhibits in the other cases. We reserve rights to

supplement this list, as our investigation is still ongoing.

Given the timing, I propose that we move the contemplated M&C to Monday, Oct. 2, on which I am

currently flexible from 1pm to 5:30pm CT. Thanks, and I look forward to continuing our

conversation.

Justin

Justin D. Kingsolver

Crowell & Moring LLP

jkingsolver@crowell.com

+1.202.624.2927 direct

From: Kingsolver, Justin 

Sent: Sunday, September 24, 2023 9:18 PM

To: 'Farrell, Timothy' <Timothy.Farrell@ropesgray.com>; Smith, Nicholas

<Nicholas.Smith@ropesgray.com>

Cc: Pine, Michael <Mpine@crowell.com>; Zagnoli, Charles <Charles.Zagnoli@ropesgray.com>;

Bushofsky, Jeffrey J. <Jeffrey.Bushofsky@ropesgray.com>; Hibbert, Kelly <KHibbert@crowell.com>

Subject: RE: BCBS v. Walgreens - Walgreens Fourth Notice of Inadvertent Disclosure

Hi Tim,

Yes, we are in agreement. Those are the rights which my email intended to reserve, so thank you for

the clarifying question. Regarding the meet-and-confer later this week, I could do Thursday at 4:00

or 4:30pm CT, but if your team needs any more time to review the list we send over, we can call an

audible on Thursday morning and move the M&C to Monday, Oct. 2 (when I am currently flexible

after 1pm CT).

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 29 of 172 PageID #:10828
Thanks,

Justin

Justin D. Kingsolver

Crowell & Moring LLP

jkingsolver@crowell.com

+1.202.624.2927 direct

From: Farrell, Timothy <Timothy.Farrell@ropesgray.com> 

Sent: Friday, September 22, 2023 1:53 PM

To: Kingsolver, Justin <JKingsolver@crowell.com>; Smith, Nicholas

<Nicholas.Smith@ropesgray.com>

Cc: Pine, Michael <Mpine@crowell.com>; Zagnoli, Charles <Charles.Zagnoli@ropesgray.com>;

Bushofsky, Jeffrey J. <Jeffrey.Bushofsky@ropesgray.com>; Hibbert, Kelly <KHibbert@crowell.com>

Subject: RE: BCBS v. Walgreens - Walgreens Fourth Notice of Inadvertent Disclosure

External Email

Justin,

Thank you for sending over this authority, which we’ll review in advance of a meet and confer next

week. We will need to some to evaluate your list of which documents have been introduced at

deposition or hearing; however Thursday and Friday are challenging as I have a deposition and

mediation respectively. Could you do late Thursday (4CT) or early Friday (8 or 9 CT)? 

As to your proposed extension, we believe the parties are likely in agreement. However, we are not

quite sure what would be implicated by our agreement that your clients “would not waive any

rights.” To be clear, we would agree that this extension to October 11 would not impact your clients’

ability to file a Motion to Compel related to the documents in Walgreens’ September 1 Inadvertent

Disclosure Notice based on the privilege objections you’ve articulated, and that the parties would

each retain the same rights or arguments as if you had filed the motion by the original deadline of

September 25. Walgreens would raise no timeliness objection if your motion was filed by October

11. If this matches your understanding, then we agree to the proposed October 11 deadline.

Thanks,

Tim

Timothy R. Farrell

ROPES & GRAY LLP

T +1 312 845 1209 | M +1 646 337 9376

191 North Wacker Drive, 32nd Floor

Chicago, IL 60606

Timothy.Farrell@ropesgray.com

www.ropesgray.com

pronouns: he/him/his

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 30 of 172 PageID #:10829
This message (including attachments) is privileged and confidential. If you are not the intended recipient,

please delete it without further distribution and reply to the sender that you have received the message in

error.

From: Kingsolver, Justin <JKingsolver@crowell.com> 

Sent: Thursday, September 21, 2023 7:23 PM

To: Smith, Nicholas <Nicholas.Smith@ropesgray.com>; Farrell, Timothy

<Timothy.Farrell@ropesgray.com>

Cc: Mpine@crowell.com; Zagnoli, Charles <Charles.Zagnoli@ropesgray.com>; Bushofsky, Jeffrey J.

<Jeffrey.Bushofsky@ropesgray.com>; KHibbert@crowell.com

Subject: RE: BCBS v. Walgreens - Walgreens Fourth Notice of Inadvertent Disclosure

Counsel:

Thanks for your note. We conferred and agreed to hold off on filing our motion to permit the

parties a bit more time to engage in a meet-and-confer. We propose an additional 10 business days,

meaning if any motion still needs to be filed at the conclusion of the M&C process, it would be filed

Wednesday, October 11. (We would exclude Yom Kippur and Indigenous People’s/Columbus Day

from the business-day count.) We agree to this timeline contingent on your agreement, as you

expressed during today’s meet-and-confer, that our filing a motion by October 11 would not waive

any rights nor would it be deemed a withdrawal or waiver of any of Plaintiffs’ objections to

Walgreens’ assertion of privilege. Please let us know by 5pm ET tomorrow if you agree.

Regarding authority, I believe we discussed sending precedent related to waiver (as a result of

Walgreens’ production of the same documents in prior litigation). But we are happy to provide

some authority on the selective redaction issue, too. A few of those authorities are below.

On “selective redaction” (and, given our discussion, by this we mean document for which

Walgreens’ counsel has already applied redactions that you now appear to be seeking to

redact in new and additional places):

Hubert v. Oswego Junction Enters. LLC, No. 21 C 3360, 2022 WL 17986707, at *2 (N.D.

Ill. Dec. 29, 2022).

Baxter Travenol Labs., Inc. v. Abbott Labs., 117 F.R.D. 119, 121 (N.D. Ill. 1987).

Golden Valley Microwave Foods, Inc. v. Weaver Popcorn Co., Inc., 132 F.R.D. 204, 207

(N.D. Ind. 1990).

On waiver:

Ctr. Partners, Ltd. v. Growth Head GP, LLC, 981 N.E.2d 345, 345, 365-66 (Ill. 2012).

Patrick v. City of Chicago, 154 F. Supp. 3d 705, 715 (N.D. Ill. 2015).

Harmony Gold U.S.A., Inc. v. FASA Corp., 169 F.R.D. 113, 117 (N.D. Ill. 1996) (2-week

delay constituted waiver).

Cent. Die Casting & Mfg. Co. v. Tokheim Corp., No. 93 C 7692, 1994 WL 444796, at *5

(N.D. Ill. Aug. 15, 1994) (3-month delay constituted waiver).

Carmody v. Bd. of Trustees of Univ. of Illinois, 893 F.3d 397, 406 (7th Cir. 2018) (1-week

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 31 of 172 PageID #:10830
delay did not constitute waiver).

As we agree to your proposal to extend this deadline, we also must reiterate what we

said during the M&C: should your team instruct – directly or indirectly – Walgreens’

counsel in other litigation to claw back these documents, as has occurred before in

similar situations, that will have no impact on our argument that Walgreens has long

ago waived the privilege over these documents produced in Russo/Forth and Humana,

as they have been in the possession of third-parties (and litigation opponents, to boot)

for years.

We will follow up by Wednesday (but hopefully sooner) with a list of clawed-back documents

introduced in depositions or arbitral hearings. (Michael and I will both be away on Monday for the

holiday.) We should be in a position to further M&C on Thursday or Friday, so if you want to

propose a few times, that would be helpful.

Thanks,

Justin

Justin D. Kingsolver

Crowell & Moring LLP

jkingsolver@crowell.com

+1.202.624.2927 direct

From: Smith, Nicholas <Nicholas.Smith@ropesgray.com> 

Sent: Thursday, September 21, 2023 2:09 PM

To: Kingsolver, Justin <JKingsolver@crowell.com>; Farrell, Timothy

<Timothy.Farrell@ropesgray.com>

Cc: Pine, Michael <Mpine@crowell.com>; Zagnoli, Charles <Charles.Zagnoli@ropesgray.com>;

Bushofsky, Jeffrey J. <Jeffrey.Bushofsky@ropesgray.com>; Hibbert, Kelly <KHibbert@crowell.com>

Subject: RE: BCBS v. Walgreens - Walgreens Fourth Notice of Inadvertent Disclosure

External Email

Justin, Michael,

Thank you for your time on the meet and confer this afternoon. We believe it was a productive start

to the meet and confer process, which we hope continues next week once your team has had a

chance to review the redacted documents produced earlier today.

We look forward to seeing your promised list of clawed back documents that you argue were

introduced at prior evidentiary hearings or depositions. This information will certainly help us

evaluate our response to your positions in advance of your filing of any motion to compel.

Additionally, we appreciate your offer to send authority that supports your position with regards to

what you’ve termed Walgreens’ alleged “selective redaction.”

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 32 of 172 PageID #:10831
As discussed, please let us know when next week your team can be available for the continued meet

and confer discussion.

Best,

Nick

Nicholas W. Smith

ROPES & GRAY LLP

T +1 312 845 1384

191 North Wacker Drive, 32nd Floor

Chicago, IL 60606

Nicholas.Smith@ropesgray.com

www.ropesgray.com

This message (including attachments) is privileged and confidential. If you are not the intended recipient,

please delete it without further distribution and reply to the sender that you have received the message in

error.

From: "Kingsolver, Justin" <JKingsolver@crowell.com>

Date: September 21, 2023 at 12:42:10 AM CDT

To: "Farrell, Timothy" <Timothy.Farrell@ropesgray.com>

Cc: mpine@crowell.com, "Zagnoli, Charles" <Charles.Zagnoli@ropesgray.com>,

"Bushofsky, Jeffrey J." <Jeffrey.Bushofsky@ropesgray.com>, KHibbert@crowell.com

Subject: RE: BCBS v. Walgreens - Walgreens Fourth Notice of Inadvertent Disclosure

We can discuss during the M&C tomorrow whether there is a reasonable prospect that

further time would help the parties come to any agreement. But as I explained below,

we do not believe that more time would be productive, since it appears the parties

have a true disagreement on privilege law. While I do hope to hear tomorrow that

Walgreens plans to reverse course and withdraw its clawbacks as to each one of these

127 documents, I think that is unlikely and, without such a proposal, that disagreement

will persist and will need to be resolved by the Court. 

Justin D. Kingsolver

Crowell & Moring LLP

jkingsolver@crowell.com

+1.202.624.2927 direct

-----Original Message-----

From: Farrell, Timothy <Timothy.Farrell@ropesgray.com> 

Sent: Wednesday, September 20, 2023 8:36 PM

To: Kingsolver, Justin <JKingsolver@crowell.com>

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 33 of 172 PageID #:10832
Farrell Decl. 

Exhibit 9 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 34 of 172 PageID #:10833
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 35 of 172 PageID #:10834 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 1 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 36 of 172 PageID #:10835 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 2 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 37 of 172 PageID #:10836 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 3 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 38 of 172 PageID #:10837 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 4 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 39 of 172 PageID #:10838 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 5 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 40 of 172 PageID #:10839 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 6 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 41 of 172 PageID #:10840 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 7 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 42 of 172 PageID #:10841 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 8 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 43 of 172 PageID #:10842 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 9 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 44 of 172 PageID #:10843 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 10 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 45 of 172 PageID #:10844 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 11 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 46 of 172 PageID #:10845 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 12 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 47 of 172 PageID #:10846 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 13 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 48 of 172 PageID #:10847 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 14 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 49 of 172 PageID #:10848 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 15 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 50 of 172 PageID #:10849 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 16 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 51 of 172 PageID #:10850 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 17 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 52 of 172 PageID #:10851 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 18 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 53 of 172 PageID #:10852 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 19 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 54 of 172 PageID #:10853 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 20 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 55 of 172 PageID #:10854 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 21 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 56 of 172 PageID #:10855 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 22 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 57 of 172 PageID #:10856 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 23 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 58 of 172 PageID #:10857 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 24 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 59 of 172 PageID #:10858 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 25 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 60 of 172 PageID #:10859 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 26 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 61 of 172 PageID #:10860 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 27 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 62 of 172 PageID #:10861 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 28 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 63 of 172 PageID #:10862 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 29 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 64 of 172 PageID #:10863 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 30 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 65 of 172 PageID #:10864 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 31 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 66 of 172 PageID #:10865 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 32 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 67 of 172 PageID #:10866 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 33 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 68 of 172 PageID #:10867 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 34 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 69 of 172 PageID #:10868 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 35 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 70 of 172 PageID #:10869 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 36 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 71 of 172 PageID #:10870 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 37 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 72 of 172 PageID #:10871 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 38 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 73 of 172 PageID #:10872 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 39 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 74 of 172 PageID #:10873 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 40 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 75 of 172 PageID #:10874 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 41 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 76 of 172 PageID #:10875 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 42 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 77 of 172 PageID #:10876 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 43 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 78 of 172 PageID #:10877 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 44 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 79 of 172 PageID #:10878 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 45 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 80 of 172 PageID #:10879 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 46 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 81 of 172 PageID #:10880 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 47 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 82 of 172 PageID #:10881 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 48 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 83 of 172 PageID #:10882 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 49 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 84 of 172 PageID #:10883 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 50 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 85 of 172 PageID #:10884 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 51 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 86 of 172 PageID #:10885 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 52 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 87 of 172 PageID #:10886 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 53 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 88 of 172 PageID #:10887 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 54 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 89 of 172 PageID #:10888 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 55 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 90 of 172 PageID #:10889 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 56 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 91 of 172 PageID #:10890 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 57 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 92 of 172 PageID #:10891 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 58 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 93 of 172 PageID #:10892 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 59 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 94 of 172 PageID #:10893 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 60 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 95 of 172 PageID #:10894 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 61 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 96 of 172 PageID #:10895 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 62 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 97 of 172 PageID #:10896 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 63 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 98 of 172 PageID #:10897 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 64 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 99 of 172 PageID #:10898 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 65 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 100 of 172 PageID #:10899 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 66 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 101 of 172 PageID #:10900 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 67 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 102 of 172 PageID #:10901 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 68 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 103 of 172 PageID #:10902 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 69 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 104 of 172 PageID #:10903 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 70 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 105 of 172 PageID #:10904 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 71 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 106 of 172 PageID #:10905 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 72 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 107 of 172 PageID #:10906 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 73 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 108 of 172 PageID #:10907 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 74 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 109 of 172 PageID #:10908 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 75 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 110 of 172 PageID #:10909 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 76 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 111 of 172 PageID #:10910 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 77 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 112 of 172 PageID #:10911 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 78 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 113 of 172 PageID #:10912 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 79 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 114 of 172 PageID #:10913 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 80 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 115 of 172 PageID #:10914 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 81 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 116 of 172 PageID #:10915 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 82 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 117 of 172 PageID #:10916 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 83 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 118 of 172 PageID #:10917 Case 1:12-cv-00300-JPO Document 22 Filed 01/18/17 Page 84 of 84
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 119 of 172 PageID #:10918 Case 1:12-cv-00300-JPO Document 22-1 Filed 01/18/17 Page 1 of 3
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 120 of 172 PageID #:10919 Case 1:12-cv-00300-JPO Document 22-1 Filed 01/18/17 Page 2 of 3
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 121 of 172 PageID #:10920 Case 1:12-cv-00300-JPO Document 22-1 Filed 01/18/17 Page 3 of 3
Farrell Decl. 

Exhibit 10 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 122 of 172 PageID #:10921
Filed Under Seal 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 123 of 172 PageID #:10922
Farrell Decl. 

Exhibit 11 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 124 of 172 PageID #:10923
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 125 of 172 PageID #:10924
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 126 of 172 PageID #:10925
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 127 of 172 PageID #:10926
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 128 of 172 PageID #:10927
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 129 of 172 PageID #:10928
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 130 of 172 PageID #:10929
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 131 of 172 PageID #:10930
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 132 of 172 PageID #:10931
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 133 of 172 PageID #:10932
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 134 of 172 PageID #:10933
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 135 of 172 PageID #:10934
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 136 of 172 PageID #:10935
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 137 of 172 PageID #:10936
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 138 of 172 PageID #:10937
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 139 of 172 PageID #:10938
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 140 of 172 PageID #:10939
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 141 of 172 PageID #:10940
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 142 of 172 PageID #:10941
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 143 of 172 PageID #:10942
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 144 of 172 PageID #:10943
Farrell Decl. 

Exhibit 12 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 145 of 172 PageID #:10944
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 146 of 172 PageID #:10945 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 1 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 147 of 172 PageID #:10946 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 2 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 148 of 172 PageID #:10947 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 3 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 149 of 172 PageID #:10948 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 4 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 150 of 172 PageID #:10949 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 5 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 151 of 172 PageID #:10950 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 6 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 152 of 172 PageID #:10951 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 7 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 153 of 172 PageID #:10952 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 8 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 154 of 172 PageID #:10953 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 9 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 155 of 172 PageID #:10954 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 10 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 156 of 172 PageID #:10955 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 11 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 157 of 172 PageID #:10956 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 12 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 158 of 172 PageID #:10957 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 13 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 159 of 172 PageID #:10958 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 14 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 160 of 172 PageID #:10959 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 15 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 161 of 172 PageID #:10960 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 16 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 162 of 172 PageID #:10961 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 17 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 163 of 172 PageID #:10962 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 18 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 164 of 172 PageID #:10963 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 19 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 165 of 172 PageID #:10964 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 20 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 166 of 172 PageID #:10965 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 21 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 167 of 172 PageID #:10966 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 22 of 23
Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 168 of 172 PageID #:10967 Case 1:12-cv-00300-JPO Document 53 Filed 01/24/19 Page 23 of 23
Farrell Decl. 

Exhibit 13 

 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 169 of 172 PageID #:10968
Filed Under Seal 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 170 of 172 PageID #:10969
Farrell Decl. 

Exhibit 14 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 171 of 172 PageID #:10970
Filed Under Seal 

Case: 1:20-cv-01853 Document #: 492 Filed: 11/01/23 Page 172 of 172 PageID #:10971